Therapeutic faecal microbiota transplantation: current status and future developments

被引：94

作者：

Borody, Thomas J. ^{[1
]}

Brandt, Lawrence J. ^{[2
,3
]}

Paramsothy, Sudarshan ^{[4
]}

机构：

[1] Ctr Digest Dis, Sydney, NSW, Australia

[2] Albert Einstein Coll Med, Bronx, NY 10467 USA

[3] Montefiore Med Ctr, Bronx, NY 10467 USA

[4] St Vincents Hosp, Sch Clin, Darlinghurst, NSW 2010, Australia

来源：

CURRENT OPINION IN GASTROENTEROLOGY | 2014年 / 30卷 / 01期

关键词：

Clostridium difficile; colitis; Crohn's disease; faecal microbiota transplantation; inflammatory bowel disease; irritable bowel syndrome; sclerosing cholangitis; INTESTINAL MICROBIOTA; ULCERATIVE-COLITIS; CHRONIC CONSTIPATION; BOWEL-FLORA; BACTERIOTHERAPY; OBESITY; SAFETY;

D O I：

10.1097/MOG.0000000000000027

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Purpose of reviewFaecal microbiota transplantation (FMT) has undergone dramatic progression over the past year and continues to evolve as knowledge of the gastrointestinal microbiota (GiMb) develops. This review summarizes therapeutic advances in FMT, latest FMT therapies and presents the potential of FMT therapeutics in other gastrointestinal and extra-intestinal conditions.Recent findingsThe GiMb is now known to have a central role in the pathogenesis of many diseases. The success of FMT in curing Clostridium difficile infection (CDI) is well established and preliminary findings in other gastrointestinal conditions are promising. Published data from over 500 CDI cases suggest that FMT is generally well tolerated with minimal side effects. The commercial potential of FMT is being explored with several products under development, including frozen GiMb extract, which has been shown highly effective in treating relapsing CDI. Such products will likely become more available in coming years and revolutionize the availability and method of delivery of GiMb.SummaryRecent literature unequivocally supports the use of FMT in treating relapsing CDI. Trials are underway to determine the therapeutic potential of FMT in other conditions, particularly inflammatory bowel disease. Therapeutic FMT is a dynamic field with new and emerging indications along with ongoing developments in optimal mode of administration.

引用

页码：97 / 105

页数：9

共 43 条

[41] Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome [J].

Vrieze, Anne ;

Van Nood, Els ;

Holleman, Frits ;

Salojarvi, Jarkko ;

Kootte, Ruud S. ;

Bartelsman, Joep F. W. M. ;

Dallinga-Thie, Geesje M. ;

Ackermans, Mariette T. ;

Serlie, Mireille J. ;

Oozeer, Raish ;

Derrien, Muriel ;

Druesne, Anne ;

Vlieg, Johan E. T. Van Hylckama ;

Bloks, Vincent W. ;

Groen, Albert K. ;

Heilig, Hans G. H. J. ;

Zoetendal, Erwin G. ;

Stroes, Erik S. ;

de Vos, Willem M. ;

Hoekstra, Joost B. L. ;

Nieuwdorp, Max .

GASTROENTEROLOGY, 2012, 143 (04) :913-+

[42]

Zhang FM, 2012, AM J GASTROENTEROL, V107, P1755, DOI 10.1038/ajg.2012.251

[43] Analysis of the Gut Microbiota in the Old Order Amish and Its Relation to the Metabolic Syndrome [J].

Zupancic, Margaret L. ;

Cantarel, Brandi L. ;

Liu, Zhenqiu ;

Drabek, Elliott F. ;

Ryan, Kathleen A. ;

Cirimotich, Shana ;

Jones, Cheron ;

Knight, Rob ;

Walters, William A. ;

Knights, Daniel ;

Mongodin, Emmanuel F. ;

Horenstein, Richard B. ;

Mitchell, Braxton D. ;

Steinle, Nanette ;

Snitker, Soren ;

Shuldiner, Alan R. ;

Fraser, Claire M. .

PLOS ONE, 2012, 7 (08)

← 1 2 3 4 5 →